A search of TCGA data sets using cBioPortal for kinases within the 3q amplicon has identified several potential oncogenes for targetable therapy, including PIK3CA, in addition to PRKCI, MAP3K13, TNIK, and PAK2. There is preferential amplification of these genes with at least one gene being amplified in more than 40% of LSCC, 35% of ESCC, 19% of CvSCC, and 15% of HNSCC compared to other cancers (Figure 2). This evidence concerns the gene PRKCI and cancer.